Mobocertinib suppresses tumor growth in patient-derived xenograft models of NSCLC with HER2 exon 20 A775_G776insYVMA78, whereas in genetically engineered mouse models with the same mutation, responses are only partial and transient. This evidence concerns the gene ERBB2 and neoplasm.